Chennai-based pharmaceutical formulations firm Linux Laboratories has secured $70 million in fairness capital from ChrysCapital and Tata Capital Healthcare Fund III (TCHF III), because it appears to broaden into new therapeutic areas and make investments additional in manufacturing and analysis.

The transaction contains a mixture of major capital and a secondary buy, with ChrysCapital buying a major minority stake in Linux.

It additionally contains the total exit of Tata Capital Healthcare Fund II (TCHF II), which is exiting with roughly 4x returns. Tata Capital Healthcare Fund is continuous its investment in Linux via TCHF III.

Avendus Capital acted because the unique monetary adviser to Linux on the transaction.

Funding to help enlargement

Linux stated the funding can be used to deepen its presence in its core specialties and enter adjoining therapeutic areas.

The corporate additionally plans to proceed buying pharmaceutical manufacturers and make investments additional in manufacturing and analysis and improvement capabilities.

“Linux was constructed on the conviction {that a} centered, science-led portfolio with affordability and entry to high quality healthcare can compete with the most important gamers in Indian pharma,” stated S Ananda Kumar, co-founder and govt director of Linux Laboratories.

“ChrysCapital and Tata Capital Healthcare Fund III carry the sector expertise and capital to take that conviction right into a a lot bigger enterprise, and we thank TCHF II for 5 years of partnership on the journey up to now,” he added.

What does Linux Laboratories do?

Based in 2007 and headquartered in Chennai, Linux operates a speciality-focused home formulations enterprise with greater than 125 manufacturers spanning about 400 stock-keeping models (SKUs).

Its portfolio has a robust give attention to central nervous system (CNS) therapies, protecting epilepsy, neuropathic ache, melancholy and autism. The corporate has additionally expanded into dermatology, cardio-diabetics and nutraceuticals.

Linux has grown via a mixture of growing its personal manufacturers and acquisitions. The corporate stated it has built-in and scaled the Biomedica and Indiabulls Prescribed drugs portfolios, alongside manufacturers acquired from Cipla and Dr. Reddy’s Laboratories.

It additionally operates its personal manufacturing facility, which the corporate describes as WHO-GMP-certified. The ability helps backward integration for its branded formulations enterprise in addition to a rising contract improvement and manufacturing operation.

Linux additionally has an export presence in worldwide markets.

ChrysCapital takes vital minority stake

ChrysCapital stated the funding was in step with its technique of backing home formulations firms centered on continual therapies.

“ChrysCapital is worked up to companion with Linux in the course of the subsequent section of its progress and is deeply impressed by its specialty-focused franchise, rigorous execution, and M&A monitor report,” stated Kshitij Sheth, managing director at ChrysCapital Advisors.

“This funding aligns with ChrysCapital’s technique of backing fast-growing home formulations firms centered on continual therapies and led by dynamic entrepreneurs,” he added.

Tata Capital Healthcare Fund, in the meantime, stated its determination to reinvest via TCHF III mirrored its continued confidence in Linux’s founders, administration staff and long-term progress prospects.

The funding comes as India’s branded formulations market continues to draw investor curiosity. Linux stated that is being pushed by the rising burden of continual and sub-chronic circumstances and the rising share of specialty-led, prescriber-facing portfolios.

With the brand new capital, the corporate plans to strengthen its present therapeutic companies, broaden into adjoining areas, pursue additional model acquisitions and enhance funding in manufacturing and R&D.